Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
|
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 50 条
  • [1] Repurposing Antihypertensive Drugs for the Prevention of Glaucoma: A Mendelian Randomization Study
    Liu, Jingjing
    Li, Shuang
    Hu, Yang
    Qiu, Shizheng
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2022, 11 (10): : 12 - 12
  • [2] Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease
    Law, Christine Shing Wei
    Yeong, Keng Yoon
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (09) : 1716 - 1730
  • [3] Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study
    Du, Kai
    Li, Ao
    Zhang, Chen-Yu
    Li, Shu-Ming
    Chen, Ping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study
    Zheng, He
    Chen, Chaolei
    Feng, Yingqing
    ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)
  • [5] Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study
    Geurts, Sven
    Tilly, Martijn J.
    Lu, Zuolin
    Stricker, Bruno H. C.
    Deckers, Jaap W.
    de Groot, Natasja M. S.
    Miller, Clint L.
    Ikram, M. Arfan
    Kavousi, Maryam
    HYPERTENSION, 2024, 81 (08) : 1766 - 1775
  • [6] Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study
    Williams, Dylan M.
    Hagg, Sara
    Pedersen, Nancy L.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2019, 109 (01): : 90 - 98
  • [7] Repurposing Antihypertensive and Statin Medications for Spinal Pain: A Mendelian Randomization Study
    Suri, Pradeep
    Elgaeva, Elizaveta E.
    Williams, Frances M. K.
    Freidin, Maxim B.
    Verzun, Dmitrii A.
    Tsepilov, Yakov A.
    SPINE, 2023, 48 (22) : 1568 - 1574
  • [8] Stroke and Alzheimer's Disease: A Mendelian Randomization Study
    Wang, Tao
    Ni, Qing-bin
    Wang, Kun
    Han, Zhifa
    Sun, Bao-liang
    FRONTIERS IN GENETICS, 2020, 11
  • [9] Parkinson's disease and Alzheimer's disease: a Mendelian randomization study
    Han, Zhifa
    Tian, Rui
    Ren, Peng
    Zhou, Wenyang
    Wang, Pingping
    Luo, Meng
    Jin, Shuilin
    Jiang, Qinghua
    BMC MEDICAL GENETICS, 2018, 19
  • [10] Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer's disease: a Mendelian randomization study
    Ou, Ya-Nan
    Yang, Yu-Xiang
    Shen, Xue-Ning
    Ma, Ya-Hui
    Chen, Shi-Dong
    Dong, Qiang
    Tan, Lan
    Yu, Jin-Tai
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)